Sim&Cure

About Sim&Cure

Sim&Cure, founded in 2014, is a medical technology company based in Montpellier, France, that is focused on securing endovascular treatments for cerebral aneurysms. The company was established by Mathieu Sanchez, who holds a PhD in biomechanics and previously worked as an R&D engineer at Philips Healthcare, and Professor Vincent Costalat, an MD, PhD, and the head of the neuroradiology department at the Montpellier University Hospital. The founding was driven by Sanchez's vision to apply his research in biomechanics to a real-world business solution after completing his PhD, which led to his collaboration with Costalat.

The company develops a software suite that utilizes digital twin and artificial intelligence technologies to assist clinicians in planning and optimizing neurovascular procedures. The core product, Sim&Size, is a CE-marked medical device that creates patient-specific 3D simulations to predict the deployment and positioning of various intracranial implants like flow diverters and stents before surgery. This allows neuro-radiologists to virtually test different device sizes and types, helping them select the optimal implant for each patient's unique anatomy. The primary benefit is a reduction in the risks associated with implant oversizing, which occurs in a high percentage of cases and can lead to treatment failure. By improving the accuracy of device selection, the software aims to decrease surgery time, cost, and patient risk. The company serves hospitals, clinicians, and large medical technology companies such as Medtronic, Stryker, and Philips.

Sim&Cure has expanded its product line to cover the entire patient journey, from screening (Sim&Predict) and therapeutic strategy (Sim&Treat) to physician training (Sim&Train). The company operates in a neurovascular device market and generates revenue through its software solutions. Since its inception, Sim&Cure has treated over 15,000 patients and established a global presence, including a subsidiary in the United States opened in 2019. The company has secured funding through multiple rounds, including a Series A led by Elaia and IT-Translation, to support its research, development, and international expansion.